Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Lisinopril prices in Germany, the highest-cost reporting region, rose 6.1% in H1 2026, climbing from USD 82.0/KG in Q1 to USD 87.0/KG by Q2 as firmer proline-derived synthesis intermediate costs and growing cardiovascular and hypertension pharmaceutical formulation demand drove consistent buying. Globally, the average rose from USD 53.6/KG in Q1 to USD 56.8/KG in Q2, a 6.0% gain. For H2 2026, a global average of USD 57.50-63.50/KG is expected, with continued firming on Middle East supply disruptions and growing chronic disease management and generic pharmaceutical sector demand.
Lisinopril is a long-acting angiotensin-converting enzyme inhibitor produced through a multi-step chemical synthesis starting from L-proline and lysine-derived intermediates, yielding a white crystalline powder extensively used in cardiovascular medicine. The largest pull comes from pharmaceutical formulations for the treatment of hypertension, where lisinopril is one of the most widely prescribed first-line antihypertensive agents across regulated and emerging markets due to its once-daily dosing and established clinical safety profile. Additional demand comes from heart failure management as part of guideline-directed medical therapy, diabetic nephropathy progression prevention where ACE inhibitor therapy slows kidney function decline, post-myocardial infarction cardiac protection protocols, and combination antihypertensive products pairing lisinopril with hydrochlorothiazide. Proline and lysine derivative synthesis intermediate costs, pharmaceutical formulation sector demand, generic pharmaceutical market competition, and regional API production capacity all feed into the price.
The balance of supply and demand for lisinopril through H2 2026 leans moderately firm. Proline-derived synthesis intermediate costs firmed from Middle East chemical supply chain disruptions. Hypertension and cardiovascular pharmaceutical demand is growing strongly with expanding generic medicine access programmes across South and Southeast Asia and Africa, where hypertension prevalence is rising.
The main upside risk is a sustained synthesis intermediate cost increase alongside accelerating hypertension prevalence in emerging market populations. The main downside risk is continued Chinese lisinopril API surplus and aggressive generic pharmaceutical pricing that limits global price recovery.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 57.50 - 63.50 | Synthesis cost firming and cardiovascular demand support |
| United States | 61.50 - 67.50 | Steady hypertension and heart failure demand holds firm |
| China | 41.00 - 47.00 | Large API capacity keeps it the most affordable |
| Germany | 88.50 - 94.50 | High synthesis and energy costs keep it the most expensive |
| India | 61.50 - 67.50 | Growing chronic disease demand holds a firm middle |
US lisinopril prices averaged USD 69.1/KG in Q2 2026, up 6.0% from USD 65.2/KG in Q1 2026. Firmer synthesis intermediate costs and consistent cardiovascular and hypertension pharmaceutical formulation procurement supported buying through the quarter.
Why did the price of Lisinopril change in Q2 2026 in the United States?
Firmer proline and lysine derivative synthesis intermediate costs raised the API production cost floor. Cardiovascular and hypertension pharmaceutical formulation procurement lifted buying from API suppliers. Heart failure and diabetic nephropathy combination product demand provided additional consistent buying support.
Chinese lisinopril prices averaged USD 43.2/KG in Q2 2026, up 5.9% from USD 40.8/KG in Q1 2026, the lowest among the tracked markets. Spring pharmaceutical export and domestic formulation procurement lifted buying. Firmer domestic synthesis intermediate costs raised the production floor despite large domestic API capacity.
Why did the price of Lisinopril change in Q2 2026 in China?
Spring pharmaceutical formulation export procurement and domestic cardiovascular drug demand lifted buying from API producers. Firmer domestic synthesis intermediate costs raised the production cost floor. Large domestic lisinopril API capacity kept China the most affordable source.
German lisinopril prices averaged USD 87.0/KG in Q2 2026, up 6.1% from USD 82.0/KG in Q1 2026, the highest among the tracked markets. Higher synthesis intermediate and energy costs elevated European API production economics. Consistent hypertension, heart failure, and combination product demand maintained consistent buying.
Why did the price of Lisinopril change in Q2 2026 in Germany?
Higher proline-derived synthesis intermediate and energy costs elevated European API production economics. Middle East supply disruptions added import cost premiums to intermediate supply chains. Consistent hypertension, heart failure management, and combination antihypertensive demand maintained consistent pharmaceutical procurement.
Indian lisinopril prices averaged USD 64.5/KG in Q2 2026, up 6.1% from USD 60.8/KG in Q1 2026. Growing hypertension and cardiovascular pharmaceutical demand supported buying. Firmer import-linked synthesis intermediate costs raised the production floor through the quarter.
Why did the price of Lisinopril change in Q2 2026 in India?
Growing hypertension and cardiovascular formulation demand lifted procurement from domestic API and formulation producers. Firmer import-linked synthesis intermediate costs raised the production floor. Middle East freight premiums elevated the landed cost of imported lisinopril API and intermediates.
US lisinopril prices averaged USD 65.2/KG in Q1 2026, recovering on the quarter. Cardiovascular and hypertension demand and firming synthesis costs held the production floor near USD 65.2/KG.
Why did the price of Lisinopril change in Q1 2026 in the United States?
Cardiovascular and hypertension formulation demand maintained consistent buying. Firmer synthesis intermediate costs held the production floor. The market recovered from the Q3 2025 API softening near USD 65.2/KG.
Chinese prices averaged USD 40.8/KG in Q1 2026, recovering on the quarter. Post-Lunar New Year pharmaceutical restocking and firmer synthesis costs held the market near USD 40.8/KG.
Why did the price of Lisinopril change in Q1 2026 in China?
Post-Lunar New Year pharmaceutical export and domestic restocking lifted buying. Firmer synthesis intermediate costs raised the production floor. The market recovered to USD 40.8/KG from the Q3 2025 level.
German prices averaged USD 82.0/KG in Q1 2026, recovering on the quarter. Hypertension and heart failure demand and firm synthesis and energy costs held the production floor near USD 82.0/KG.
Why did the price of Lisinopril change in Q1 2026 in Germany?
Hypertension and cardiovascular demand maintained buying. Firm synthesis intermediate and energy costs held the elevated production floor. The market recovered to USD 82.0/KG from the Q3 2025 API softening.
Indian prices averaged USD 60.8/KG in Q1 2026, recovering on the quarter. Growing cardiovascular and hypertension demand and firmer synthesis costs held the market near USD 60.8/KG.
Why did the price of Lisinopril change in Q1 2026 in India?
Growing hypertension and cardiovascular demand maintained buying. Firmer synthesis intermediate costs raised the production floor. The market recovered to USD 60.8/KG from the Q3 2025 level.
Global lisinopril prices dipped briefly in Q3 2025 on seasonal API synthesis softness before recovering steadily through Q4 2025, Q1 2026, and Q2 2026. The average eased from USD 52.0/KG in Q2 2025 to USD 51.5/KG in Q3, then firmed to USD 52.5/KG in Q4, USD 53.6/KG in Q1 2026, and USD 56.8/KG in Q2 2026, a net gain of about 9.2% over the window. Synthesis intermediate cost cycles and cardiovascular pharmaceutical sector demand drove the consistent recovery.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 56.8 | +6.0% | ↑ Rising |
| Q1 2026 | 53.6 | +2.1% | ↑ Rising |
| Q4 2025 | 52.5 | +2.0% | ↑ Rising |
| Q3 2025 | 51.5 | -1.0% | ↓ Falling |
| Q2 2025 | 52.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Lisinopril prices followed a broadly stable path through 2025 with a brief Q3 API synthesis softening. The global average opened at USD 51.8/KG in Q1 2025 and closed near USD 52.5/KG in Q4, a marginal full-year gain of about 1.4%. Consistent cardiovascular and hypertension demand and synthesis intermediate cost cycles drove the quarterly pattern.
US prices firmed from about USD 62.5/KG in Q1 2025 to USD 63.0/KG by Q4, a gain of 0.8%. Consistent hypertension and cardiovascular formulation demand and stable synthesis costs maintained a broadly flat market through the year.
Chinese prices fell from roughly USD 40.2/KG in Q1 2025 to USD 39.5/KG by Q4, a decline of 1.7%. Large domestic lisinopril API capacity and competitive export pricing maintained the lowest price level throughout.
German prices firmed from about USD 78.5/KG in Q1 2025 to USD 79.5/KG by Q4, a gain of 1.3%. Consistent hypertension, heart failure, and combination product demand and firm synthesis and energy costs supported the market throughout the year.
Indian prices firmed from roughly USD 58.0/KG in Q1 2025 to USD 58.8/KG by Q4, a gain of 1.4%. Growing chronic disease management and hypertension formulation demand drove the consistent firming through the year.
Expert Market Research: Your Source for Real-Time Lisinopril Price Intelligence
Expert Market Research tracks lisinopril prices continuously across every major producing and consuming region. The team traces causation through proline and lysine derivative synthesis intermediate economics, cardiovascular pharmaceutical sector demand cycles, and regional API production capacity. Contact Expert Market Research today for lisinopril pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Pharmaceutical formulations for hypertension treatment as one of the most widely prescribed first-line antihypertensive agents take the largest share. Heart failure management, diabetic nephropathy progression prevention, post-myocardial infarction protection, and combination antihypertensive products also consume significant volumes globally.
The Q2 2026 average was USD 69.1/KG in the United States, USD 43.2/KG in China, USD 87.0/KG in Germany, and USD 64.5/KG in India. Germany remains the highest-priced market.
The global average rose from USD 53.6/KG in Q1 to about USD 56.8/KG in Q2, a gain of around 6.0%. Firmer synthesis intermediate costs and growing cardiovascular formulation demand drove the H1 firming.
Seasonal synthesis intermediate cost softening reduced the API production cost floor. Post-season pharmaceutical procurement moderation reduced buying urgency before the Q4 2025 and H1 2026 demand-led recovery.
The global average is expected in the USD 57.50 to 63.50/KG range for H2 2026, with continued firming as synthesis intermediate costs stay elevated and hypertension and cardiovascular sector demand grows across emerging markets.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on cardiovascular demand, and China prices lowest on large domestic API production capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to proline and lysine derivative synthesis intermediate costs, hypertension prevalence trends, and generic pharmaceutical market competition. Chinese API production levels and Middle East chemical supply events are key signals.
Asia Pacific leads with China and India holding the largest lisinopril API synthesis capacity, followed by Europe. Any synthesis intermediate or proline derivative cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time cardiovascular formulation contracts around API production cycles, build cover when synthesis intermediate signals tightening, and monitor Chinese API output as the primary supply signal.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.